Literature DB >> 33453152

Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.

Xuejun Chen1, Tongqing Zhou1, Stephen D Schmidt1, Hongying Duan1, Cheng Cheng1, Gwo-Yu Chuang1, Ying Gu1, Mark K Louder1, Bob C Lin1, Chen-Hsiang Shen1, Zizhang Sheng2, Michelle X Zheng1, Nicole A Doria-Rose1, M Gordon Joyce3, Lawrence Shapiro4, Ming Tian5, Frederick W Alt5, Peter D Kwong6, John R Mascola7.   

Abstract

Vaccine elicitation of broadly neutralizing antibodies (bnAbs) is a key HIV-research goal. The VRC01 class of bnAbs targets the CD4-binding site on the HIV-envelope trimer and requires extensive somatic hypermutation (SHM) to neutralize effectively. Despite substantial progress, vaccine-induced VRC01-class antibodies starting from unmutated precursors have exhibited limited neutralization breadth, particularly against viruses bearing glycan on loop D residue N276 (glycan276), present on most circulating strains. Here, using sequential immunization of immunoglobulin (Ig)-humanized mice expressing diverse unmutated VRC01-class antibody precursors, we elicited serum responses capable of neutralizing viruses bearing glycan276 and isolated multiple lineages of VRC01-class bnAbs, including two with >50% breadth on a 208-strain panel. Crystal structures of representative bnAbs revealed the same mode of recognition as known VRC01-class bnAbs. Structure-function studies further pinpointed key mutations and correlated their induction with specific immunizations. VRC01-class bnAbs can thus be matured by sequential immunization from unmutated ancestors to >50% breadth, and we delineate immunogens and regimens inducing key SHM.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HIV-1 vaccine; antibody VRC01; broadly neutralizing antibody; glyan276; somatic hypermutation

Year:  2021        PMID: 33453152      PMCID: PMC8020832          DOI: 10.1016/j.immuni.2020.12.014

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  48 in total

1.  Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

Authors:  Jinghe Huang; Byong H Kang; Elise Ishida; Tongqing Zhou; Trevor Griesman; Zizhang Sheng; Fan Wu; Nicole A Doria-Rose; Baoshan Zhang; Krisha McKee; Sijy O'Dell; Gwo-Yu Chuang; Aliaksandr Druz; Ivelin S Georgiev; Chaim A Schramm; Anqi Zheng; M Gordon Joyce; Mangaiarkarasi Asokan; Amy Ransier; Sam Darko; Stephen A Migueles; Robert T Bailer; Mark K Louder; S Munir Alam; Robert Parks; Garnett Kelsoe; Tarra Von Holle; Barton F Haynes; Daniel C Douek; Vanessa Hirsch; Michael S Seaman; Lawrence Shapiro; John R Mascola; Peter D Kwong; Mark Connors
Journal:  Immunity       Date:  2016-11-15       Impact factor: 31.745

2.  Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains.

Authors:  M Gordon Joyce; Ivelin S Georgiev; Yongping Yang; Aliaksandr Druz; Hui Geng; Gwo-Yu Chuang; Young Do Kwon; Marie Pancera; Reda Rawi; Mallika Sastry; Guillaume B E Stewart-Jones; Angela Zheng; Tongqing Zhou; Misook Choe; Joseph G Van Galen; Rita E Chen; Christopher R Lees; Sandeep Narpala; Michael Chambers; Yaroslav Tsybovsky; Ulrich Baxa; Adrian B McDermott; John R Mascola; Peter D Kwong
Journal:  Cell Rep       Date:  2017-12-05       Impact factor: 9.423

3.  Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.

Authors:  Xueling Wu; Charlene Wang; Sijy O'Dell; Yuxing Li; Brandon F Keele; Zhongjia Yang; Hiromi Imamichi; Nicole Doria-Rose; James A Hoxie; Mark Connors; George M Shaw; Richard T Wyatt; John R Mascola
Journal:  J Virol       Date:  2012-03-14       Impact factor: 5.103

4.  HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.

Authors:  Joseph G Jardine; Takayuki Ota; Devin Sok; Matthias Pauthner; Daniel W Kulp; Oleksandr Kalyuzhniy; Patrick D Skog; Theresa C Thinnes; Deepika Bhullar; Bryan Briney; Sergey Menis; Meaghan Jones; Mike Kubitz; Skye Spencer; Yumiko Adachi; Dennis R Burton; William R Schief; David Nemazee
Journal:  Science       Date:  2015-06-18       Impact factor: 47.728

5.  Cloning and expression of murine Ig genes from single B cells.

Authors:  Thomas Tiller; Christian E Busse; Hedda Wardemann
Journal:  J Immunol Methods       Date:  2009-08-27       Impact factor: 2.303

6.  HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.

Authors:  Johannes F Scheid; Joshua A Horwitz; Yotam Bar-On; Edward F Kreider; Ching-Lan Lu; Julio C C Lorenzi; Anna Feldmann; Malte Braunschweig; Lilian Nogueira; Thiago Oliveira; Irina Shimeliovich; Roshni Patel; Leah Burke; Yehuda Z Cohen; Sonya Hadrigan; Allison Settler; Maggi Witmer-Pack; Anthony P West; Boris Juelg; Tibor Keler; Thomas Hawthorne; Barry Zingman; Roy M Gulick; Nico Pfeifer; Gerald H Learn; Michael S Seaman; Pamela J Bjorkman; Florian Klein; Sarah J Schlesinger; Bruce D Walker; Beatrice H Hahn; Michel C Nussenzweig; Marina Caskey
Journal:  Nature       Date:  2016-06-22       Impact factor: 49.962

7.  Conservation, Compensation, and Evolution of N-Linked Glycans in the HIV-1 Group M Subtypes and Circulating Recombinant Forms.

Authors:  Simon A Travers
Journal:  ISRN AIDS       Date:  2012-12-19

8.  Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.

Authors:  Pia Dosenovic; Lotta von Boehmer; Amelia Escolano; Joseph Jardine; Natalia T Freund; Alexander D Gitlin; Andrew T McGuire; Daniel W Kulp; Thiago Oliveira; Louise Scharf; John Pietzsch; Matthew D Gray; Albert Cupo; Marit J van Gils; Kai-Hui Yao; Cassie Liu; Anna Gazumyan; Michael S Seaman; Pamela J Björkman; Rogier W Sanders; John P Moore; Leonidas Stamatatos; William R Schief; Michel C Nussenzweig
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

9.  Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques.

Authors:  Ann J Hessell; J Pablo Jaworski; Erin Epson; Kenta Matsuda; Shilpi Pandey; Christoph Kahl; Jason Reed; William F Sutton; Katherine B Hammond; Tracy A Cheever; Philip T Barnette; Alfred W Legasse; Shannon Planer; Jeffrey J Stanton; Amarendra Pegu; Xuejun Chen; Keyun Wang; Don Siess; David Burke; Byung S Park; Michael K Axthelm; Anne Lewis; Vanessa M Hirsch; Barney S Graham; John R Mascola; Jonah B Sacha; Nancy L Haigwood
Journal:  Nat Med       Date:  2016-03-21       Impact factor: 53.440

10.  Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.

Authors:  Joseph G Jardine; Devin Sok; Jean-Philippe Julien; Bryan Briney; Anita Sarkar; Chi-Hui Liang; Erin A Scherer; Carole J Henry Dunand; Yumiko Adachi; Devan Diwanji; Jessica Hsueh; Meaghan Jones; Oleksandr Kalyuzhniy; Michael Kubitz; Skye Spencer; Matthias Pauthner; Karen L Saye-Francisco; Fabian Sesterhenn; Patrick C Wilson; Denise M Galloway; Robyn L Stanfield; Ian A Wilson; Dennis R Burton; William R Schief
Journal:  PLoS Pathog       Date:  2016-08-25       Impact factor: 6.823

View more
  13 in total

1.  A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.

Authors:  Peng Zhang; Elisabeth Narayanan; Qingbo Liu; Yaroslav Tsybovsky; Kristin Boswell; Shilei Ding; Zonghui Hu; Dean Follmann; Yin Lin; Huiyi Miao; Hana Schmeisser; Denise Rogers; Samantha Falcone; Sayda M Elbashir; Vladimir Presnyak; Kapil Bahl; Madhu Prabhakaran; Xuejun Chen; Edward K Sarfo; David R Ambrozak; Rajeev Gautam; Malcom A Martin; Joanna Swerczek; Richard Herbert; Deborah Weiss; Johnathan Misamore; Giuseppe Ciaramella; Sunny Himansu; Guillaume Stewart-Jones; Adrian McDermott; Richard A Koup; John R Mascola; Andrés Finzi; Andrea Carfi; Anthony S Fauci; Paolo Lusso
Journal:  Nat Med       Date:  2021-12-09       Impact factor: 53.440

Review 2.  Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination.

Authors:  Zekun Mu; Barton F Haynes; Derek W Cain
Journal:  Curr Opin Virol       Date:  2021-11-04       Impact factor: 7.121

3.  SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.

Authors:  M Gordon Joyce; Wei-Hung Chen; Rajeshwer S Sankhala; Agnes Hajduczki; Paul V Thomas; Misook Choe; William Chang; Caroline E Peterson; Elizabeth Martinez; Elaine B Morrison; Clayton Smith; Aslaa Ahmed; Lindsay Wieczorek; Alexander Anderson; Rita E Chen; James Brett Case; Yifan Li; Therese Oertel; Lorean Rosado; Akshaya Ganesh; Connor Whalen; Joshua M Carmen; Letzibeth Mendez-Rivera; Christopher Karch; Neelakshi Gohain; Zuzana Villar; David McCurdy; Zoltan Beck; Jiae Kim; Shikha Shrivastava; Ousman Jobe; Vincent Dussupt; Sebastian Molnar; Ursula Tran; Chandrika B Kannadka; Michelle Zemil; Htet Khanh; Weimin Wu; Matthew A Cole; Debra K Duso; Larry W Kummer; Tricia J Lang; Shania E Muncil; Jeffrey R Currier; Shelly J Krebs; Victoria R Polonis; Saravanan Rajan; Patrick M McTamney; Mark T Esser; William W Reiley; Morgane Rolland; Natalia de Val; Michael S Diamond; Gregory D Gromowski; Gary R Matyas; Mangala Rao; Nelson L Michael; Kayvon Modjarrad
Journal:  bioRxiv       Date:  2021-05-10

4.  SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.

Authors:  M Gordon Joyce; Wei-Hung Chen; Rajeshwer S Sankhala; Agnes Hajduczki; Paul V Thomas; Misook Choe; Elizabeth J Martinez; William C Chang; Caroline E Peterson; Elaine B Morrison; Clayton Smith; Rita E Chen; Aslaa Ahmed; Lindsay Wieczorek; Alexander Anderson; James Brett Case; Yifan Li; Therese Oertel; Lorean Rosado; Akshaya Ganesh; Connor Whalen; Joshua M Carmen; Letzibeth Mendez-Rivera; Christopher P Karch; Neelakshi Gohain; Zuzana Villar; David McCurdy; Zoltan Beck; Jiae Kim; Shikha Shrivastava; Ousman Jobe; Vincent Dussupt; Sebastian Molnar; Ursula Tran; Chandrika B Kannadka; Sandrine Soman; Caitlin Kuklis; Michelle Zemil; Htet Khanh; Weimin Wu; Matthew A Cole; Debra K Duso; Larry W Kummer; Tricia J Lang; Shania E Muncil; Jeffrey R Currier; Shelly J Krebs; Victoria R Polonis; Saravanan Rajan; Patrick M McTamney; Mark T Esser; William W Reiley; Morgane Rolland; Natalia de Val; Michael S Diamond; Gregory D Gromowski; Gary R Matyas; Mangala Rao; Nelson L Michael; Kayvon Modjarrad
Journal:  Cell Rep       Date:  2021-12-08       Impact factor: 9.995

Review 5.  Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.

Authors:  Wilton B Williams; Kevin Wiehe; Kevin O Saunders; Barton F Haynes
Journal:  J Int AIDS Soc       Date:  2021-11       Impact factor: 5.396

6.  Protocol to identify and monitor key mutations of broadly neutralizing antibody lineages following sequential immunization of Ig-humanized mice.

Authors:  Xuejun Chen; Stephen D Schmidt; Hongying Duan; Nicole A Doria-Rose; John R Mascola
Journal:  STAR Protoc       Date:  2022-02-18

7.  Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer.

Authors:  Jeong Hyun Lee; Catherine Nakao; Michael Appel; Amber Le; Elise Landais; Oleksandr Kalyuzhniy; Xiaozhen Hu; Alessia Liguori; Tina-Marie Mullen; Bettina Groschel; Robert K Abbott; Devin Sok; William R Schief; Shane Crotty
Journal:  Cell Rep       Date:  2022-03-08       Impact factor: 9.423

Review 8.  HIV vaccinology: 2021 update.

Authors:  Jeong Hyun Lee; Shane Crotty
Journal:  Semin Immunol       Date:  2021-07-14       Impact factor: 10.671

9.  Engineering an Antibody V Gene-Selective Vaccine.

Authors:  Larance Ronsard; Ashraf S Yousif; Julianne Peabody; Vintus Okonkwo; Pascal Devant; Alemu Tekewe Mogus; Ralston M Barnes; Daniel Rohrer; Nils Lonberg; David Peabody; Bryce Chackerian; Daniel Lingwood
Journal:  Front Immunol       Date:  2021-09-09       Impact factor: 7.561

Review 10.  A Structural Update of Neutralizing Epitopes on the HIV Envelope, a Moving Target.

Authors:  Emma Parker Miller; Maxwell T Finkelstein; Molly C Erdman; Paul C Seth; Daniela Fera
Journal:  Viruses       Date:  2021-09-05       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.